available at www.sciencedirect.com
journal homepage: www.europeanurology.com

European Association of Urology

Corrigendum

Corrigendum to: "Re: The Efficacy and Safety of Degarelix: A 12-Month, Comparative, Randomized, Open-Label, Parallel-Group Phase III Study in Patients with Prostate Cancer" by Dieter Jocham and Christian Doehn [Eur Urol 2009;55:1488–9]

Bo-Eric Persson [a,b]

[a] *Ferring Pharmaceuticals, St-Prex, Switzerland*
[b] *Elisabethsjukhuset, Uppsala, Sweden*

Please note the following inaccuracies published in the above mentioned Words of Wisdom contribution published in the June 2009 issue of European Urology.

1) The article mentions the recent regulatory approvals of degarelix by the FDA and EMEA, but unfortunately the approved dose stated is incorrect (240/160 mg). The approved dose is **240 mg s.c. followed by 80 mg s.c. every month**.

2) The authors refer to the incidence of injection site pain as 40% in degarelix patients. In fact, this value refers to the incidence of injection site reactions (which include pain, erythema, swelling, induration and nodule at the injection site). The true incidence of injection site pain was 29% in the pooled degarelix treatment arms.

It is important that the approved dose is accurately presented, to avoid unnecessary prescription/dosing errors.

DOI of original article: 10.1016/j.eururo.2009.03.039
E-mail address: Bo-Eric.Persson@ferring.com.
0302-2838/$ – see back matter doi:10.1016/j.eururo.2009.05.023